Abstract
BackgroundCombination of Venetoclax, a BCL-2 inhibitor, and 5-Azacytidine, a hypomethylating agent, is the standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are not candidates for...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
